 |
|
|
| |
GS-6620: A Liver Targeted Nucleotide Prodrug with Potent Pan-Genotype Anti-Hepatitis C Virus Activity In Vitro
|
| |
| |
Reported by Jules Levin EASL 2011 Berlin Mrch 31-Apr 2
A Ray, J Feng, T Wang, K Wong, L Zhang, D Babusis, J Vela, T Butler, J Xu, V Aktoudianakis, R Lee, D Sauer, I Henne, M Fenaux, H Mo, W Zhong, S Metobo, J Perry, C Kim, and A Cho
Gilead Sciences, Inc., Foster City, CA, USA
References
1. M Fenaux, G Cheng, E Mabery, et al. GS-6620, a Novel Anti-Hepatitis C virus
Nucleotide Prodrug, has a High In Vitro Barrier to Resistance. Poster No. 1205,
EASL 2011
2. G Cheng, M Fenaux, E Mabery, et al. Nucleotide Inhibitor Resistance Selections Using GT2a Infectious Virus: PSI-7851 and GS-6620 Select for a Novel Resistance Pathway Including Substitutions of M289V/L Followed by S282T. Poster No.1198, EASL 2011
3. E Lawitz, J Lalezari, M Rodriquez-Torres, et al. Clinical synergy of an Anti-HCV nucleoside analog with SOC: Viral kinetics of PSI-7977 with SOC. Hepatology 2010; 52 (4 Suppl 1):706a
4. D Jensen, H Wedemeyer, R Herring, et al. High rates of early viral response,
promising safety profi le and lack of resistance-related breakthrough in HCV GT1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned week 12 interim analysis from the PROPEL study. Hepatology 201; 52(4 suppl 1):360a
|
| |
|
|
|
|
|
